Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 26.88
-0.08 (-0.30%)
Jul 9, 2026, 4:08 PM HKT
Everest Medicines Market Cap
Everest Medicines has a market cap or net worth of 9.45 billion as of July 9, 2026. Its market cap has decreased by -44.37% in one year.
Market Cap
9.45B
Enterprise Value
7.44B
Revenue
1.90B
Ranking
n/a
PE Ratio
n/a
Stock Price
26.88
Market Cap Chart
Since October 9, 2020, Everest Medicines's market cap has decreased from 20.64B to 9.45B, a decrease of -54.22%. That is a compound annual growth rate of -12.71%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jul 9, 2026 | 9.45B | -27.69% |
| Dec 31, 2025 | 13.06B | -16.21% |
| Dec 31, 2024 | 15.59B | 132.87% |
| Dec 29, 2023 | 6.70B | 24.60% |
| Dec 30, 2022 | 5.37B | -47.96% |
| Dec 31, 2021 | 10.33B | -47.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GenFleet Therapeutics (Shanghai) | 12.65B |
| Ascletis Pharma | 12.24B |
| TenNor Therapeutics (Suzhou) | 10.17B |
| Nanjing Leads Biolabs | 9.92B |
| HBM Holdings | 9.92B |
| CARsgen Therapeutics Holdings | 9.10B |
| Suzhou Ribo Life Science | 8.85B |
| CStone Pharmaceuticals | 8.55B |